Neuroimmunological disorders: JAK in the itch
Nature Reviews Drug Discovery 16, 753 (2017).
doi:10.1038/nrd.2017.204
Author: Yvonne Bordon
Reflexes such as coughing and scratching help to expel pathogens and other potentially harmful substances. These reflex responses are also associated with chronic inflammatory diseases, such as asthma and atopic dermatitis, but the mechanisms involved are not well understood. Oetjen et al. now show (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 30, 2017 Category: Drugs & Pharmacology Authors: Yvonne Bordon Tags: Research Highlight Source Type: research
Cancer immunotherapy: When viruses attack
Nature Reviews Drug Discovery 16, 752 (2017).
doi:10.1038/nrd.2017.220
Author: Anna Dart
A limitation to the efficacy of immune checkpoint inhibitors is their dependence on a pre-existing antitumour immunity. Therefore, strategies to overcome tumour immunosuppression may improve the antitumour activity of current immunotherapies. Two studies now suggest this could be achieved with oncolytic virotherapy.Ribas et al (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 30, 2017 Category: Drugs & Pharmacology Authors: Anna Dart Tags: Research Highlight Source Type: research
Respiratory diseases: Gq protein inhibition induces airway relaxation
Nature Reviews Drug Discovery 16, 752 (2017).
doi:10.1038/nrd.2017.203
Author: Sarah Crunkhorn
Currently available therapies for obstructive airway diseases, such as asthma, bronchitis and chronic obstructive pulmonary diseases (COPD), may be limited by poor disease control, adverse effects or a lack of efficacy. Writing in Science Translational Medicine, Matthey et al. now demonstrate that pharmacological (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 30, 2017 Category: Drugs & Pharmacology Authors: Sarah Crunkhorn Tags: Research Highlight Source Type: research
Anticancer therapy: Holding the thought
Nature Reviews Drug Discovery 16, 751 (2017).
doi:10.1038/nrd.2017.216
Author: M. Teresa Villanueva
High-grade gliomas (HGGs) are the most lethal type of brain tumour in both children and adults. The heterogeneous nature of these tumours and the lack of targetable mutations have hampered the development of effective therapies. Now, a group, led by Michelle Monje, has described how (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 30, 2017 Category: Drugs & Pharmacology Authors: M. Teresa Villanueva Tags: Research Highlight Source Type: research
Nora Volkow
Nature Reviews Drug Discovery 16, 746 (2017).
doi:10.1038/nrd.2017.215
Nearly 35,000 Americans die each year due to opioid overdose, around the same number that die in car crashes. Despite attempts from doctors and policy makers to quell this epidemic, the rate of overdose death continues to rise. Nora Volkow, Director of the National Institute on Drug Abuse (NIDA), and Francis Collins, Director of the NIH, announced earlier this year in the New England Journal of Medicine that the NIH is working with industry and regulatory partners to set up a public–private partnership (PPP) that will accelerate the discov...
Source: Nature Reviews Drug Discovery - October 30, 2017 Category: Drugs & Pharmacology Tags: News and Analysis Source Type: research
FDA unveils searchable adverse events system
Nature Reviews Drug Discovery 16, 743 (2017).
doi:10.1038/nrd.2017.224
Author: Asher Mullard
The FDA has launched a new adverse event portal that enables drug developers, doctors and patients to search for safety red flags for approved drugs. This FDA Adverse Event Reporting System (FAERS) could offer a powerful post-marketing pharmacovigilance resource and a means of guiding (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 30, 2017 Category: Drugs & Pharmacology Authors: Asher Mullard Tags: News and Analysis Source Type: research
$ 215 million cancer immunotherapy biomarker consortium debuts
Nature Reviews Drug Discovery 16, 743 (2017).
doi:10.1038/nrd.2017.223
Author: Asher Mullard
The NIH and 11 biopharmaceutical companies have partnered to identify, develop and validate new biomarkers that will accelerate the development of cancer immunotherapies.Because these drugs recruit the immune system to kill tumours, conventional criteria for measuring responses to cancer therapies may not effectively capture (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 30, 2017 Category: Drugs & Pharmacology Authors: Asher Mullard Tags: News and Analysis Source Type: research
Cancer mouse models carry genomic inconsistencies
Nature Reviews Drug Discovery 16, 743 (2017).
doi:10.1038/nrd.2017.222
Author: Asher Mullard
Preclinical disease models are always flawed. In the case of patient-derived xenograft (PDX) mouse models of human cancer, a new study in Nature Genetics has catalogued some of the ways in which these 'avatars' lead scientists astray.PDX models of cancer — in which (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 30, 2017 Category: Drugs & Pharmacology Authors: Asher Mullard Tags: News and Analysis Source Type: research
Preclinical antibiotic pipeline gets a pick-me-up
Nature Reviews Drug Discovery 16, 741 (2017).
doi:10.1038/nrd.2017.213
Author: Asher Mullard
CARB-X, a public–private partnership aimed at bolstering the antibiotic pipeline, funded a diverse set of 17 early-stage drug development projects in its first year. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 30, 2017 Category: Drugs & Pharmacology Authors: Asher Mullard Tags: News and Analysis Source Type: research
Landmark gene therapy poised for US approval
Nature Reviews Drug Discovery 16, 739 (2017).
doi:10.1038/nrd.2017.212
Author: Chris Morrison
The FDA is weighing the fate of Spark Therapeutics' voretigene neparvovec, potentially the first among a wave of new gene therapies. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 30, 2017 Category: Drugs & Pharmacology Authors: Chris Morrison Tags: News and Analysis Source Type: research
Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications
Nature Reviews Drug Discovery 17, 19 (2018).
doi:10.1038/nrd.2017.194
Authors: Hsin-Pei Shih, Xiaodan Zhang & Alex M. Aronov
The productivity of the pharmaceutical industry has been widely discussed in recent years, particularly with regard to concerns that substantial expenditures on research and development have failed to translate into approved drugs. Various analyses of this productivity challenge have focused on aspects such as attrition (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 27, 2017 Category: Drugs & Pharmacology Authors: Hsin-Pei Shih Xiaodan Zhang Alex M. Aronov Tags: Analysis Source Type: research
Trends in GPCR drug discovery: new agents, targets and indications
Nature Reviews Drug Discovery 16, 829 (2017).
doi:10.1038/nrd.2017.178
Authors: Alexander S. Hauser, Misty M. Attwood, Mathias Rask-Andersen, Helgi B. Schiöth & David E. Gloriam
G protein-coupled receptors (GPCRs) are the most intensively studied drug targets, mostly due to their substantial involvement in human pathophysiology and their pharmacological tractability. Here, we report an up-to-date analysis of all GPCR drugs and agents in clinical trials, which reveals current trends across molecule (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 27, 2017 Category: Drugs & Pharmacology Authors: Alexander S. Hauser Misty M. Attwood Mathias Rask-Andersen Helgi B. Schi ö th David E. Gloriam Tags: Analysis Source Type: research
Trial watch: Tracing investment in drug development for Alzheimer disease
Nature Reviews Drug Discovery 16, 819 (2017).
doi:10.1038/nrd.2017.169
Authors: Alpha Tom Kodamullil, Firas Zekri, Meemansa Sood, Bastian Hengerer, Luc Canard, Duncan McHale & Martin Hofmann-Apitius
The high failure rates of drug R&D for Alzheimer disease (AD) — and particularly the recent failures of several drugs that target the amyloid cascade in phase III trials — have raised questions about the relative emphasis on particular therapeutic strategies for AD. Here, we (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 23, 2017 Category: Drugs & Pharmacology Authors: Alpha Tom Kodamullil Firas Zekri Meemansa Sood Bastian Hengerer Luc Canard Duncan McHale Martin Hofmann-Apitius Tags: News and Analysis Source Type: research
Legacy data sharing to improve drug safety assessment: the eTOX project
Nature Reviews Drug Discovery 16, 811 (2017).
doi:10.1038/nrd.2017.177
Authors: Ferran Sanz, François Pognan, Thomas Steger-Hartmann, Carlos Díaz, Montserrat Cases, Manuel Pastor, Philippe Marc, Joerg Wichard, Katharine Briggs, David K. Watson, Thomas Kleinöder, Chihae Yang, Alexander Amberg, Maria Beaumont, Anthony J. Brookes, Søren Brunak, Mark T. D. Cronin, Gerhard F. Ecker, Sylvia Escher, Nigel Greene, Antonio Guzmán, Anne Hersey, Pascale Jacques, Lieve Lammens, Jordi Mestres, Wolfgang Muster, Helle Northeved, Marc Pinches, Javier Saiz, Nicolas Sajot, Alfonso Valencia, Johan van der Lei...
Source: Nature Reviews Drug Discovery - October 13, 2017 Category: Drugs & Pharmacology Authors: Ferran Sanz Fran ç ois Pognan Thomas Steger-Hartmann Carlos D í az Montserrat Cases Manuel Pastor Philippe Marc Joerg Wichard Katharine Briggs David K. Watson Thomas Klein ö der Chihae Yang Alexander Amberg Maria Beaumont Anthony J. Brookes S ø ren Br Tags: Comment Source Type: research
Bispecific antibody pipeline moves beyond oncology
Nature Reviews Drug Discovery 16, 810 (2017).
doi:10.1038/nrd.2017.211
Author: Asher Mullard
Nature Reviews Drug Discovery16, 666–668 (2017)The spelling of John Haurum's last name was incorrect. The error has been corrected in the html and pdf versions online. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 13, 2017 Category: Drugs & Pharmacology Authors: Asher Mullard Tags: Erratum Source Type: research
